TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05016882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0194 0499 50 mg/mL
Description: Patients will receive subcutaneous (s.c., under the skin) injections of NNC0194-0499 once weekly The study will last for about 19 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0194 0499 50 mg/mL
Description: Patients will receive subcutaneous (s.c., under the skin) injections of NNC0194-0499 once weekly The study will last for about 19 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0194 0499 50 mg/mL
Description: Patients will receive subcutaneous (s.c., under the skin) injections of NNC0194-0499 once weekly The study will last for about 19 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0194 0499 50 mg/mL
Description: Patients will receive subcutaneous (s.c., under the skin) injections of NNC0194-0499 once weekly The study will last for about 19 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NNC0194-0499)
Description: Patients will receive subcutaneous (s.c., under the skin) injections of placebo once weekly The study will last for about 19 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (NNC0194-0499)
Description: Patients will receive subcutaneous (s.c., under the skin) injections of placebo once weekly The study will last for about 19 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NNC0194-0499)
Description: Patients will receive subcutaneous (s.c., under the skin) injections of placebo once weekly The study will last for about 19 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NNC0194-0499)
Description: Patients will receive subcutaneous (s.c., under the skin) injections of placebo once weekly The study will last for about 19 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 3 mg/mL
Description: Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide once weekly The study will last for about 19 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 3 mg/mL
Description: Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide once weekly The study will last for about 19 months
Study: NCT06043882

Intervention type: PROCEDURE
Intervention: flexible bronchoscopy
Description: fiberoptic bronchoscopy was done where biopsies were taken either by conventional TBNA (c-TBNA) , EBUS-TBNA or direct forceps biopsies and sent for histopathological examination
Study: NCT04857957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral dose CNTX-6016 or oral dose Placebo
Description: CNTX-6016 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral dose CNTX-6016 or oral dose Placebo
Description: CNTX-6016 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral dose CNTX-6016 or oral dose Placebo
Description: CNTX-6016 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral dose CNTX-6016 or oral dose Placebo
Description: CNTX-6016 or Placebo
Study: NCT05016882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 3 mg/mL
Description: Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide once weekly The study will last for about 19 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide 3 mg/mL
Description: Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide once weekly The study will last for about 19 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide placebo
Description: Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide placebo once weekly The study will last for about 19 months
Study: NCT04989192

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Scan at CT scanner 1
Description: Patients will undergo imaging on a modern CT scanner with spectral imaging capabilities. A dose neutral spectral acquisition mode will routinely be used. Contrast material protocol and scan ranges are similar among all three arms.
Study: NCT05016882

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Semaglutide placebo
Description: Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide placebo once weekly The study will last for about 19 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Semaglutide placebo
Description: Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide placebo once weekly The study will last for about 19 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Semaglutide placebo
Description: Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide placebo once weekly The study will last for about 19 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Semaglutide placebo
Description: Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide placebo once weekly The study will last for about 19 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0174 0833 10 mg/mL
Description: Patients will receive subcutaneous (s.c., under the skin) injections of NNC0174-0833 once weekly The study will last for about 19 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NNC0174 0833 placebo
Description: Patients will receive subcutaneous (s.c., under the skin) injections of NNC0174-0833 placebo once weekly The study will last for about 19 months
Study: NCT04605276

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04987775

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetyl Cysteine
Description: 900mg 2x daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo bid
Study: NCT05595668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prism Adaptation - 15-degree prism goggles
Description: Patients in the experimental condition will wear prism goggles while completing an iPad-administered aiming task. The prisms will shift the patients' vision 15 degrees rightward, causing a recalibration of visuo-motor information. Prism adaptation will be carried out for ten sessions for 15 minutes a day, over the span of two weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Prism Adaptation - 5-degree prism goggles
Description: 5-degree goggles are worn instead of the 15-degree prism goggles, while completing the same tasks as those assigned to the 15-degree condition.
Study: NCT05463419

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIKA COVID-19 vaccine
Description: SARS-CoV-2 spike subunit protein (Also called Recombinant SARS-CoV-2 S-trimer protein), PIKA adjuvant.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Covid-19 vaccine
Description: Inactivated SARS-CoV-2 virus
Study: NCT06116123

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Massage mattress with cube/block system
Description: Patients with an odd number were assigned to group I, while those with an even number were allocated to group II. Patients in group I were provided with a pressure sore prevention bed featuring a support surface with vibration (massage) capabilities, a cube/block system creating a low-pressure area, and a ventilation system, routinely utilized in the unit. For group II patients, a viscoelastic pressure sore prevention mattress with an orthopedic support surface, routinely employed in the unit, was used.Within the first six hours after admission, patients in both groups underwent initial assessments using the Braden Scale to determine their pressure sore risk. Both groups were monitored for a maximum of four weeks, with daily pressure ulcer assessments conducted using the Pressure Ulcer Observation Form. Pressure sore area in both groups was calculated in square centimeters (cm2) using the Wound Measurement Ruler.
Study: NCT06487910

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D scan measurment
Description: patients included in the study will undergo a 3D scan measurement of on or more burn scars. This measurement will then be digitally modified in preparation for the manufacture of the differential pressure distribution orthosis. The orthosis will then be manufactured using a 3D printing process.
Study: NCT05372367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 907828
Description: BI 907828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 907828
Description: BI 907828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole
Study: NCT06298058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIBP-A13 formulation for injection
Description: SIBP-A13: injection; strength: 1, 2, 4, 5, 6 or 8 mg; dose escalation and the first group is 1mg (intravenous infusion). Starting from the lowest dose, when the former does not meet the termination criteria, then start the next dose group study until Maximum Tolerated Dose (MTD). The study adopts a 3+3 dose increasing design. Administration period: divided into single administration and multiple administration. Single dose administration: The participants are administered a single dose on the first day for a total of 21 days of observation, and complete the examinations and evaluations specify in the protocol. If dose-limiting toxicity (DLT) does not occur, the participant enters a multiple dosing period. Multiple administration: administration every 3 weeks.
Study: NCT06497140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethiodized Oil-based emulsion
Description: Embolization of genicular arteries

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham-operation
Description: Mimicked catheterization and embolization of genicular arteries
Study: NCT06472856

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture will be given using single use sterile stainless steel 34 gauge (Japanese size: 0.20 X 30 mm) filoform needles. Skin will be swabbed with an alcohol prep pad before acupuncture is administered. Needles will be inserted 0.5 to 1.0 centimetres deep into the skin and gently manipulated to create the deqi sensation. No electrical stimulation will be used.
Study: NCT06327165

Intervention type: OTHER
Intervention: observation
Description: The ANI monitor calculates heart rate variability mediated by changes in the parasympathetic nervous system.
Study: NCT04989192

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Scan at CT scanner 2
Description: Patients will undergo imaging on a modern 128 slice CT-scanner without spectral imaging capabilities. A standard acquisition protocol will be used. Contrast material protocol and scan ranges are similar among all three arms.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Scan at CT scanner 3
Description: Patients will undergo imaging on a modern 20 slice CT-scanner without spectral imaging capabilities. A standard acquisition protocol will be used. Contrast material protocol and scan ranges are similar among all three arms.
Study: NCT06279182

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Barre Stretching Intervention
Description: The Barre stretching intervention will consist of a 15-minute recorded video session with static and isometric movements focused on the hands, wrists, shoulders, and neck combined with breathing exercises throughout each movement. A 15-minute Barre stretching video will be selected for this study because static and isometric stretching should be held for 10-15 seconds per movement and repeated 2-3 times for increasing blood flow and circulation which can improve heart rate variability (HRV), increase muscle suppleness in preparation for muscle activation through patient care, and reduce stress levels through regulation of the rate, depth, and pattern of breathing. The duration of 15-minutes provided the participants with adequate time to complete each stretching movement for a total of 45 seconds with 15 seconds rest between movements. There will be fifteen targeted stretching movements focused on the hands, wrists, shoulders, and neck region.
Study: NCT06571539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AR-assisted EVD placement
Description: Cfr. arm description

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Freehand EVD placement
Description: External ventricular drain (EVD) placement using the conventional freehand technique. This intervention covers the matched, non-concurrent control group, retrospectively obtained without active enrollment to receive study treatment.
Study: NCT06570421

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peroneal electrical transcutaneous neuromodulation (peroneal eTNM®)
Description: This is a non-invasive intervention, which utilizes direct transcutaneous, electrical stimulation of the peroneal nerve
Study: NCT06168773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol Injection
Description: to evaluate the efficacy and safety of short-term intravenous combination of low-dose haloperidol and magnesium for delirium prevention in critically ill elderly patients after elective major surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol Injection
Description: to evaluate the efficacy and safety of short-term intravenous combination of low-dose haloperidol and magnesium for delirium prevention in critically ill elderly patients after elective major surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Haloperidol Injection
Description: to evaluate the efficacy and safety of short-term intravenous combination of low-dose haloperidol and magnesium for delirium prevention in critically ill elderly patients after elective major surgery.
Study: NCT05380700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Stimulation
Description: Participants in the intervention group will be provided with up to 30 minutes of relaxing, 360-degree virtual reality (VR) stimulation and corresponding sounds, twice in 24 hours during their stay on the intermediate care unit.
Study: NCT06377501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-food, plant-based diet
Description: Subjects will be instructed to adopt a whole-food, plant-based diet for 8 weeks. They will attend weekly group cooking classes led by a RD and receive weekly health coaching sessions.
Study: NCT01134692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol, Norfloxacin, VSL#3
Description: Propranolol: as per heart rate titration Norfloxacin: 400mg BD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propranolol, Norfloxacin, VSL#3
Description: Propranolol: as per heart rate titration Norfloxacin: 400mg BD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol, Norfloxacin, VSL#3
Description: Propranolol: as per heart rate titration Norfloxacin: 400mg BD
Study: NCT05704231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Motivational Interviewing with WhatsApp video call
Description: The intervention group will be given a motivational interview with a WhatsApp video call for 3 months. Motivational interviews will be applied every two weeks, 6 times in total.
Study: NCT03537794

Intervention type: DIAGNOSTIC_TEST
Intervention: PET scans
Description: PET scans and PHNO scans

Intervention type: DIAGNOSTIC_TEST
Intervention: PET scans
Description: PET scans and PHNO scans

Intervention type: DIAGNOSTIC_TEST
Intervention: PET scans
Description: PET scans and PHNO scans
Study: NCT06500507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS4131 Injection
Description: Participants confirming to the eligibility criteria will be assigned to 1 of the 9 dose groups (0.06/0.3/1 \~ 600 ug/kg, respectively) based on the sequence of inclusion.
Study: NCT06564714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early baclofen Intervention
Description: Baclofen is initiated as soon as any sign of acute spasticity.~5 mg three times a day and is increased every 7 days by 5 mg per intake (up to a maximum 80 mg total per day) until achieving an optimal response, i.e. when spasticity is no longer problematic.

Intervention type: DRUG
Group type: OTHER
Intervention: Usual routine care
Description: Baclofen is initiated only when acute spasticity is deemed problematic.~5 mg three times a day and is increased every 7 days by 5 mg per intake (up to a maximum 80 mg total per day) until achieving an optimal response.
Study: NCT06563648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: shotblocker
Description: A ShotBlocker was placed on the arm of the patients in the ShotBlocker group during the injection, and the injection was performed from the part where the opening was located by lightly pressing with the fingertips throughout the injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: local cold application
Description: Local cold application was applied to the arm of the patients in the local cold application group for five minutes using a cold pack, and then the injection was performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ShotBlocker placebo group
Description: During the injection, the back side of the ShotBlocker was placed on the arm of the patients in the ShotBlocker placebo group and the injection was performed by gently pressing with the fingertips throughout the injection.
Study: NCT05755958

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HIFU treatment in rectal Endometriosis
Description: HIFU treatment of rectal endometriosis

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM HIFU procedure
Description: SHAM HIFU procedure
Study: NCT03925194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Application of Anakinra once daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anakinra
Description: Application of Anakinra once daily for 28 days
Study: NCT04612192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active luminette
Description: receive an active light using glasses of 1500 lux (an average of 180 photons/s/cm2, with a maximum wavelenght at 468 nm), 30-minute long light therapy in the morning, in a time period defined by sleep log and chronotype questionnaire, on a 4-week period

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo luminette
Description: receive a placebo light using glasses (an average of n photons/s/cm2, single- band spectrum with a narrow peak at 660 nm under 50 lux), with the same modality as the experimental group
Study: NCT06367101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AR training with gait and HRV feedback
Description: Use projection-based AR system to train gait and HRV. To give gait and HRV feedback for subjects after AR training.
Study: NCT06336564

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training
Description: Verbal information will be given about location, function and the correct way to contract the pelvic floor muscles (PFM). Participants will be instructed on how to perform The Knack, which is a pre-contraction of the PFM during some abdominal effort, such as coughing, sneezing or laughing. The exercises consist of two series of 10 maximum contractions sustained for 5 seconds and 10 seconds of relaxation and two series of 10 maximum rapid contractions with two seconds of maintenance and four seconds of relaxation, with one minute of rest between each series. Participants will be instructed to perform the same exercises at home (twice a day) and to fill out a training diary, allowing researchers to monitor and check whether the exercises are actually being performed. The protocol will be repeated with the researcher three times in total, every 30 to 40 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Description: Verbal information will be given about location, function and the correct way to contract the pelvic floor muscles (PFM). Participants will be instructed on how to perform The Knack, which is a pre-contraction of the PFM during some abdominal effort, such as coughing, sneezing or laughing. The exercises consist of two series of 10 maximum contractions sustained for 5 seconds and 10 seconds of relaxation and two series of 10 maximum rapid contractions with two seconds of maintenance and four seconds of relaxation, with one minute of rest between each series. Participants will be instructed to perform the same exercises at home (twice a day) and to fill out a training diary, allowing researchers to monitor and check whether the exercises are actually being performed. The protocol will be repeated with the researcher three times in total, every 30 to 40 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microablative Radiofrequency
Description: Patients will be placed in the lithotomy position and through speculum examination and under direct vision or guided by colposcope, sequential application of radiofrequency will be carried out on the vaginal walls and introitus. The Wavetronic 6000 Touch device will be used with the Megapulse HF FRAXX system (Loktal Medical Electronics, São Paulo, Brazil), equipped with an electronic energy fractionation circuit, connected to a vaginal pen with 64 microneedles, 200μm in diameter and 1 mm in length, mounted on a Teflon body and divided into a matrix of eight columns with eight needles each. In the vestibule and vaginal opening, 10% lidocaine spray will be applied three minutes before the procedure. Three applications will be carried out in the vagina/vaginal introitus, with an interval of 30 to 40 days.
Study: NCT06494748

Intervention type: OTHER
Intervention: Follow up Decision
Description: 0: No need to follow up in Intensive Care Unit~1: Need to follow up in Intensive Care Unit

Intervention type: OTHER
Intervention: Follow up Decision
Description: 0: No need to follow up in Intensive Care Unit~1: Need to follow up in Intensive Care Unit
Study: NCT04411836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Description: patients are treated with schizontocidal treatment plus a single dose of Tafenoquine (TQ).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: patients are treated with schizontocidal treatment plus high dose PQ (total dose 7 mg/kg) unsupervised over 7 days (PQ7)
Study: NCT05686356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sutezolid
Description: Sutezolid will be given at a dose of 1200mg QD in arm 1 and at a dose of 1600mg QD in arms 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sutezolid
Description: Sutezolid will be given at a dose of 1200mg QD in arm 1 and at a dose of 1600mg QD in arms 2 and 3.